Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
This is not a denial of eligibility
It is being tested in a Phase 2, multicenter, placebo-controlled, double-blind RCT for moderately to severely active UC in 207 participants aged 1875 who have inadequate response to conventional, biologic, or advanced therapies, with the primary outcome measuring clinical remission at week 12 using mMS, currently recruiting with estimated completion in August 2027 (NCT06254950)
Diabetes medications have well-established coverage frameworks across commercial and government payers
Semaglutide: How Does it Work
Sethis unique approach ensures that each patient receives personalized care tailored to their individual needs, promoting not just weight loss but overall health and well-being
Is BACE1 a suitable therapeutic target for the treatment of Alzheimers disease
